Christopher N Floyd1, Albert Ferro. 1. Department of Clinical Pharmacology, Cardiovascular Division, British Heart Foundation Centre of Research Excellence, King's College London, London, UK.
Abstract
AIM: The PlA1/A2 polymorphism of glycoprotein IIIa (GPIIIa) has been associated with both antiplatelet drug resistance and increased cardiovascular events. The aim of this study was to conduct the first meta-analysis investigating the association between carriage of the PlA2 allele and resistance to currently licensed antiplatelet drugs. METHODS: Electronic databases (MEDLINE and EMBASE) were searched for all articles evaluating genetic polymorphisms of GPIIIa. For studies where antiplatelet resistance was measured using validated techniques, pooled odds ratios (ORs) were calculated using fixed effects and random effects models. RESULTS: Sixteen studies were eligible for statistical analysis and included 1650 PlA1 homozygous subjects and 668 carriers of the PlA2 allele. For carriers of the PlA2 allele, OR 0.924 (n = 2318; 95% CI 0.743, 1.151; P = 0.481) was observed for resistance to any antiplatelet drug, OR 0.862 (n = 2085; 95% CI 0.685, 1.086; P = 0.208) for resistance to aspirin and OR 1.429 (n = 233; 95% CI 0.791, 2.582; P = 0.237) for resistance to clopidogrel. In the aspirin cohort, sub-group analysis revealed no statistical association in either healthy subjects or those with cardiovascular disease. PlA2 carriage was marginally associated with aspirin sensitivity using the fixed effects model when identified by the PFA-100 assay (n = 1151; OR 0.743, 95% CI 0.558, 0.989; P = 0.041) but with significant heterogeneity (I(2) = 55%; P = 0.002). Significance was lost with analysis using a random effects model. CONCLUSIONS: The totality of published data does not support an association between carriage of the PlA2 allele and antiplatelet drug resistance. Significant heterogeneity indicates the need for larger studies using validated and standardized assays.
AIM: The PlA1/A2 polymorphism of glycoprotein IIIa (GPIIIa) has been associated with both antiplatelet drug resistance and increased cardiovascular events. The aim of this study was to conduct the first meta-analysis investigating the association between carriage of the PlA2 allele and resistance to currently licensed antiplatelet drugs. METHODS: Electronic databases (MEDLINE and EMBASE) were searched for all articles evaluating genetic polymorphisms of GPIIIa. For studies where antiplatelet resistance was measured using validated techniques, pooled odds ratios (ORs) were calculated using fixed effects and random effects models. RESULTS: Sixteen studies were eligible for statistical analysis and included 1650 PlA1 homozygous subjects and 668 carriers of the PlA2 allele. For carriers of the PlA2 allele, OR 0.924 (n = 2318; 95% CI 0.743, 1.151; P = 0.481) was observed for resistance to any antiplatelet drug, OR 0.862 (n = 2085; 95% CI 0.685, 1.086; P = 0.208) for resistance to aspirin and OR 1.429 (n = 233; 95% CI 0.791, 2.582; P = 0.237) for resistance to clopidogrel. In the aspirin cohort, sub-group analysis revealed no statistical association in either healthy subjects or those with cardiovascular disease. PlA2 carriage was marginally associated with aspirin sensitivity using the fixed effects model when identified by the PFA-100 assay (n = 1151; OR 0.743, 95% CI 0.558, 0.989; P = 0.041) but with significant heterogeneity (I(2) = 55%; P = 0.002). Significance was lost with analysis using a random effects model. CONCLUSIONS: The totality of published data does not support an association between carriage of the PlA2 allele and antiplatelet drug resistance. Significant heterogeneity indicates the need for larger studies using validated and standardized assays.
Authors: Jerzy Dropinski; Jacek Musial; Bogdan Jakiela; Wojciech Wegrzyn; Marek Sanak; Andrew Szczeklik Journal: Thromb Haemost Date: 2005-12 Impact factor: 5.249
Authors: K Vinod Vijayan; Trevor C Huang; Yan Liu; Aubrey Bernardo; Jing Fei Dong; Pascal J Goldschmidt-Clermont; B Rita Alevriadou; Paul F Bray Journal: FEBS Lett Date: 2003-04-10 Impact factor: 4.124
Authors: Andrew L Frelinger; YouFu Li; Matthew D Linden; Marc R Barnard; Marsha L Fox; Douglas J Christie; Mark I Furman; Alan D Michelson Journal: Circulation Date: 2009-12-07 Impact factor: 29.690
Authors: Guy L Wheeler; Gregory A Braden; Paul F Bray; Stanley J Marciniak; Mary Ann Mascelli; David C Sane Journal: Am Heart J Date: 2002-01 Impact factor: 4.749
Authors: Zuzana Motovska; Petr Widimsky; Jan Kvasnicka; Robert Petr; Dana Bilkova; Jaroslava Hajkova; Iuri Marinov; Stanislav Simek; Petr Kala Journal: Blood Coagul Fibrinolysis Date: 2009-06 Impact factor: 1.276
Authors: Aino Lepäntalo; Jussi Mikkelsson; Julio C Reséndiz; Leena Viiri; Janne T Backman; Esko Kankuri; Pekka J Karhunen; Riitta Lassila Journal: Thromb Haemost Date: 2006-02 Impact factor: 5.249
Authors: Patricia A Gum; Kandice Kottke-Marchant; Patricia A Welsh; Jennifer White; Eric J Topol Journal: J Am Coll Cardiol Date: 2003-03-19 Impact factor: 24.094